Evgen Pharma PLC Publication on sulforaphane in COVID-19
07 April 2021 - 4:00PM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
07 April 2021
Evgen Pharma Plc
("Evgen" or "the Company")
Publication on sulforaphane in COVID-19
Recent pre-print publication shows in vitro and in vivo
antiviral activity of sulforaphane against the virus responsible
for COVID-19
Evgen (AIM: EVG), a clinical stage drug development company
focused on the treatment of cancer, inflammation and acute
respiratory distress syndrome notes a recent pre-print publication
from Johns Hopkins University, USA(1) . The publication
demonstrates that sulforaphane, the active ingredient in SFX-01,
prevents virus-induced cell death in vitro induced by several
variants of the SARS-CoV-2 virus and another coronavirus.
The paper goes on to demonstrate that the inhibition of
SARS-CoV-2 cytotoxicity by sulforaphane occurs both when cells are
pre-treated with sulforaphane and when sulforaphane is administered
24 hours after viral inoculation. The work also shows that
sulforaphane acts synergistically with the antiviral drug
remdesivir. The authors further established that the effects of
sulforaphane, administered orally, were observed in vivo in a mouse
model infected with the SARS-CoV-2 virus where reduction in both
viral load and lung pathology were observed. The data have been
published before peer review given the urgency of the current
pandemic.
Evgen's SFX-01 is a druggable, clinical grade medicine currently
at the clinical trial stage containing synthetic sulforaphane in a
stable complex.
Dr Huw Jones CEO of Evgen commented: "We are pleased to note
these findings from Johns Hopkins University. If the data continue
to demonstrate efficacy after peer review, they underpin and
support the hypothesis we are testing with the University of Dundee
in the STAR COVID-19 clinical study. We anticipate receiving the
outcome of the interim analysis of the first 100 patients
completing the study during this second quarter of 2021."
(1) Odronez et al, https://www.biorxiv.org/content/10.1101/2021.03.25.437060v1
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It is listed on
the AIM market of the London Stock Exchange and trades under the
ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAQQLFBFZLLBBD
(END) Dow Jones Newswires
April 07, 2021 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024